NASDAQ:LITS

Lite Strategy Q4 2026 Earnings Results & Report

$0.81 +0.01 (+1.56%)
Closing price 04:00 PM Eastern
Extended Trading
$0.81 +0.01 (+0.84%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Lite Strategy reported Q4 2026 earnings on September 28, 2026. The company reported EPS of -$0.38.

Earnings Announcement Details

Quarter
Q4 2026
Time
After Market Closes
Conference Call Date
Conference Call
7:00 AM ET

Lite Strategy EPS Results

Actual EPS
-$0.38
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Lite Strategy Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Lite Strategy Q4 2026 Earnings FAQ

Lite Strategy (NASDAQ:LITS) reported earnings of -$0.38 per share for Q4 2026. The report was announced on Monday, September 28, 2026.

Lite Strategy Earnings Headlines

Buy Stocks… A Crash is Coming
Think stocks are expensive and a crash is coming? Economist Jim Rickards says you're right, but he urges investors not to sell before hearing his 2027 prediction. He warns that by November 30th, Congress is set to make a move he believes will trigger a historic buying panic. Economists call the phenomenon a crack-up boom. Rickards is known for correctly predicting the biggest market shocks of the last 20 years.tc pixel
Lite Strategy (NASDAQ:LITS) Upgraded at Wall Street Zen
See More Lite Strategy Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Lite Strategy? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Lite Strategy and other key companies, straight to your email.

About Lite Strategy

Lite Strategy (NASDAQ:LITS) is a digital-asset treasury company focused on acquiring and holding Litecoin as a primary reserve asset. Its business centers on managing this Litecoin-focused strategy rather than providing consumer products or services.

The company was formerly known as MEI Pharma, a clinical-stage biopharmaceutical company that worked on treatments for cancer. It later shifted its business focus to a Litecoin treasury strategy.

Lite Strategy’s activities therefore primarily involve its digital-asset holdings and related treasury management; the company is not principally engaged in drug development under its current strategy.

View Lite Strategy Profile